Literature DB >> 9756800

The European Medicines Evaluation Agency: open to criticism. Transparency must be coupled with greater rigour.

K Abbasi, A Herxheimer.   

Abstract

Mesh:

Year:  1998        PMID: 9756800      PMCID: PMC1113976          DOI: 10.1136/bmj.317.7163.898

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  6 in total

1.  Secrecy and transparency of medicines licensing in the EU.

Authors:  J Abraham; G Lewis
Journal:  Lancet       Date:  1998-08-08       Impact factor: 79.321

2.  Statement of the International Working Group on transparency and accountability in drug regulation.

Authors: 
Journal:  Int J Risk Saf Med       Date:  1996

3.  European Medicines Evaluation Agency and the new licensing arrangements.

Authors: 
Journal:  Drug Ther Bull       Date:  1994-12-15

4.  The European Medicines Evaluation Agency.

Authors:  A Herxheimer
Journal:  BMJ       Date:  1996-02-17

5.  The future of healthcare systems. Method for rigorously assessing cost effectiveness of new drugs must be set up.

Authors:  P Milner; K Walshe; A Lipp; R Milne
Journal:  BMJ       Date:  1997-10-11

Review 6.  Riluzole for amyotrophic lateral sclerosis.

Authors: 
Journal:  Drug Ther Bull       Date:  1997-02
  6 in total
  2 in total

1.  European medicines evaluation agency is ahead of national licensing authorities.

Authors:  F Sauer
Journal:  BMJ       Date:  1998-10-17

Review 2.  Pharmaceutical Benefit-Risk Communication Tools: A Review of the Literature.

Authors:  Dominic Way; Hortense Blazsin; Ragnar Löfstedt; Frederic Bouder
Journal:  Drug Saf       Date:  2017-01       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.